Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples